// STATE LEGISLATION TRACKER

Michigan HB 4947 — Health: pharmaceuticals; manufacturers of products containing ephedrine or pseudoephedrine; require to participate in a

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Michigan
Bill: HB 4947
Filed: 2025-09-16
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Michigan HB4947 appears to target products containing ephedrine or pseudoephedrine by requiring manufacturers to participate in a national logging system. Based on the title and subjects provided, it does not appear to affect compounded peptides, peptide prescribing, telehealth, clinician scope, or FDA 503A/503B compounding.

Key Points

No apparent peptide-specific prescribing or compounding changes
Targets ephedrine and pseudoephedrine products, not peptide therapies
No clear effect on off-label peptide prescribing
No clear change to telehealth access for peptide patients
No apparent change to NP or naturopathic peptide-related scope

What to Watch For

Note Watch only if later text adds broader pharmacy reporting or dispensing rules.

Note Any prescription monitoring impact appears limited to ephedrine or pseudoephedrine products.

Note No peptide ecosystem impact can be inferred from the available title and subjects.

Where the Bill Stands

The provided source lists the latest action as unavailable, so the bill's current process status cannot be confirmed from the supplied information.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws